Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study.
Grande E, Giovannini M, Marriere E, Pultar P, Quinlan M, Chen X, Rahmanzadeh G, Curigliano G, Cui X. Grande E, et al. Among authors: rahmanzadeh g. Br J Clin Pharmacol. 2021 Jul;87(7):2867-2878. doi: 10.1111/bcp.14697. Epub 2020 Dec 29. Br J Clin Pharmacol. 2021. PMID: 33300203 Free PMC article. Clinical Trial.
Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours.
Chen X, Isambert N, López-López R, Giovannini M, Pognan N, Kapoor S, Quinlan M, You B, Cui X, Rahmanzadeh G, Mau-Sorensen M. Chen X, et al. Among authors: rahmanzadeh g. Br J Clin Pharmacol. 2023 Mar;89(3):1046-1055. doi: 10.1111/bcp.15544. Epub 2022 Oct 17. Br J Clin Pharmacol. 2023. PMID: 36131603 Free article.
Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Glaenzel U, Jin Y, Hansen R, Schroer K, Rahmanzadeh G, Pfaar U, Jaap van Lier J, Borell H, Meissner A, Camenisch G, Zhao S. Glaenzel U, et al. Among authors: rahmanzadeh g. Drug Metab Dispos. 2020 Oct;48(10):873-885. doi: 10.1124/dmd.119.090324. Epub 2020 Jul 14. Drug Metab Dispos. 2020. PMID: 32665418 Clinical Trial.
Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurin.
Sechaud R, Gu H, Rahmanzadeh G, Chiparus O, Breitschaft A, Menssen HD. Sechaud R, et al. Among authors: rahmanzadeh g. Cancer Chemother Pharmacol. 2024 Oct;94(4):535-547. doi: 10.1007/s00280-024-04683-3. Epub 2024 Aug 7. Cancer Chemother Pharmacol. 2024. PMID: 39110203 Clinical Trial.
Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Sechaud R, Gu H, Rahmanzadeh G, Taylor A, Chiparus O, Sharma GK, Breitschaft A, Menssen HD. Sechaud R, et al. Among authors: rahmanzadeh g. Cancer Chemother Pharmacol. 2024 Sep;94(3):487. doi: 10.1007/s00280-024-04657-5. Cancer Chemother Pharmacol. 2024. PMID: 38438807 No abstract available.
11 results